×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

cureTV – Empowering Patients Through Video

Nancy Cohen
To combat the stigma around mental health care for patients with lung cancer, survivor Nancy Cohen shares her own treatment story and why she feels it's important to include mental health care during cancer treatment.
Dr. Hossein Borghaei
Hossein Borghaei, DO, MS, of Fox Chase Cancer Center, discusses emerging treatment options for patients with lung cancer.
Dr. Brian I. Rini
When asked about the future of renal cell carcinoma (RCC) treatment, one expert is hopeful about the current search, but notes that more work is needed to find a reliable biomarker for use in patients with the most common kind of kidney cancer.
SPONSORED CONTENT
Optune caregivers offer advice and support to fellow caregivers.
Dr. Sara Hurvitz
When making treatment decisions in breast cancer, patient concerns about how each treatment will affect their daily life — and their disease stage — have an important role to play, according to Dr. Sara Hurvitz.
Dr. Sara Hurvitz
The safety profile and effectiveness of each therapeutic option are both important considerations to keep in mind when clinicians and patients weigh their breast cancer treatment options, according to one expert.
Dr. Arash Rezazadeh Kalebasty
When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of androgen-targeted therapies, making the chemotherapy agent a valid choice for some patients, according to results from the CARD trial.
Dr. Daniel Petrylak
"Sequential treatment in prostate cancer is really something that’s evolving over time," Dr. Daniel Petrylak said of the study findings presented at the European Society of Medical Oncology Congress 2019.
Dr. Daniel George
The addition of novel agents in the prostate cancer treatment landscape could create a shift in the way patients with advanced disease are treated, said Dr. Daniel George.
Dr. Sara Hurvitz
While it is the responsibility of the clinician to inform their patients of all options available, it is, in turn, vital for them to play a role in selecting the cancer treatment that’s right for them, according to Dr. Sara Hurvitz.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×